Feasibility of the loop brush EUS-FNA for characterization of pancreatic cysts: pilot clinical investigation
NCT ID NCT07814326
First seen Sep 10, 2026 · Last updated Sep 10, 2026
Summary
This investigation aims to demonstrate the feasibility of the lbFNA device for the first time in pancreatic cysts in humans. This study will be used as a base for further investigations on the safety and diagnostic accuracy of the lbFNA device.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 8 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Pancreatic cystic lesions that require surgical resection according to MDT conference * Assessed as fit for surgery * Age \>18 years * Given written informed consent to participate Exclusion Criteria: * Pregnancy * Cyst not accessible by lbFNA * Cyst not accessible for resection that includes the puncture canal for lbFNA * Cyst with calcified content * Inability to understand written or oral information, which hinders the ability to give informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pancreatic cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Surgery, Umeå University Hospital
Umeå, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A multicenter, open-label, phase II umbrella study to evaluate the efficacy and safety of the investigational product in participants with advanced or metastatic pancreatic cancer
- Can a pill duo outsmart a Hard-to-Treat pancreatic cancer mutation?
- Can a new drug combo outsmart RAS-Mutated pancreatic cancer?
- Can protein patterns in stored tumors point to new treatment targets?
- Can a triple therapy shrink pancreatic tumors enough for complete surgery?
- Personalized drug matching put to the test in pancreatic cancer